Refresco acquires AZPACK in Arizona, USA
Rotterdam, the Netherlands, November 14, 2019 – Refresco announces that it has entered into an agreement with AZPACK (Arizona Production & Packaging) to acquire their manufacturing activities located in Tempe, Arizona, USA. With this agreement, Refresco further expands its footprint in North America to enable strategic growth in this region. Refresco became the world's largest independent bottler with leadership positions across Europe and North America following the acquisition of Cott’s bottling activities last year.
Hans Roelofs, CEO Refresco Group, explains: “North America is a large and very diverse market with a lot of growth potential in different drinks categories. Our current footprint consists of 27 locations in North America, serving national and international branded beverage companies and retailers. With the addition of AZPACK to the Refresco Group, we will be even better positioned to service customers in the Southwestern USA across many categories, including energy drinks and innovative sports drinks. AZPACK will have a specialist role in the Refresco Group, as they are known for their expertise in manufacturing complex niche products for branded beverage companies.”
Adds Peter Reilly, Co-Founder of AZPACK: “We have grown our company significantly over the past decade, but recognize the need for a different and larger platform in order to continue to grow and thrive. Both Dr. Wang and I will stay on as managers to support this next growth phase. Refresco is a very experienced beverage solutions provider and they value entrepreneurship and flexibility as much as we do. Our can-do mentality perfectly matches their approach to serving customers.”
******end of press release*******
For further information, please contact:
Refresco Group, Nicole McDonald, tel. +31 61271 6869, email@example.com
In North America: Grayling NY, Ms. Niveen Saleh, tel. +1 646 284-9414, firstname.lastname@example.org
Refresco is the world's largest independent bottler of beverages for retailers and A-brands with production in Europe and North America. The company has full year volumes and revenue of circa 11 billion liters and circa €3.7 billion, respectively. Refresco offers an extensive range of product and packaging combinations from 100% fruit juices to carbonated soft drinks and mineral waters in carton, PET, Aseptic PET, cans and glass. Focused on innovation, Refresco continuously searches for new and alternative ways to improve the quality of its products and packaging combinations in line with consumer and customer demand, environmental responsibilities and market demand. Refresco is headquartered in Rotterdam, the Netherlands and has more than 9,500 employees. www.refresco.com
Arizona Production & Packaging is one of the fastest growing beverage manufacturing companies in the United States. From modest beginnings, AZPACK is now a major contract manufacturer in the Southwest, working with clients around the globe to support their bottling and canning needs. Managed by Co-Founders Peter Reilly and Dr. Yibing Wang, the company continues to pursue its original purpose: providing the finest beverages with uncompromising principles. AZPACK has a well-earned reputation of offering world-class manufacturing operations and responding quickly to customer requirements. AZPACK’s client list consists of Fortune 500 beverage companies, including makers of well-known energy drinks and nutrition and dietary supplements; they support a wide range of suppliers.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million6.12.2019 07:15:00 CET | Press release
Basel, Switzerland, December 06, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba® (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a sales milestone payment to Basilea of USD 7 million. Basilea is entitled to receive sales milestone payments upon Pfizer’s cumulative Cresemba sales in Pfizer’s licensed territories exceeding certain thresholds. The first sales milestone was triggered early in 2019 and amounted to USD 5 million. Pfizer is currently commercializing Cresemba in many European countries, including France, Germany, Italy, Spain and the U.K, as well as in Israel and in Singapore, the first launched country in the Asia Pacific region. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased that the continued strong sales performance of Cresemba has now triggered the second sales milestone from Pfizer this year. This confirms that Cresemba is addressing a high medical need and
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy6.12.2019 07:15:00 CET | Press release
Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak expiratory flow, exacerbation rates, rescue medication use versus mometasone furoate among other secondary endpoints1 Improvement in lung function was observed in high dose QMF149 versus a high dose LABA/ICS standard-of-care in certain additional secondary endpoints1 https://novartis.gcs-web.com/Novartis-Phase-III-data-on-new-inhaled-dual-combination-QMF149-show-significant-improvement-across-key-asthma-outcomes-versus-monotherapy Basel, December 6, 2019 — Novartis today announced data from the 52-week pivotal Phase III PALLADIUM clinical trial which demonstrated that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate (IND/MF) in development, was superior to mometasone furoate (MF) at medium and high doses in improving lung function, meeting the primary endpoint1.
Galapagos completes recruitment of NOVESA trial in systemic sclerosis5.12.2019 22:01:00 CET | Press release
Mechelen, Belgium; 5 December 2019, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of GLPG1690 in patients with systemic sclerosis (SSc), an autoimmune disease involving multiorgan fibrosis which has one of the highest mortality rates among rheumatic diseases1. NOVESA recruited 33 patients with diffuse cutaneous systemic sclerosis (dcSSc). One of the most visible manifestations is hardening of the skin. In dcSSc, the skin thickening is more widespread; these patients have a higher risk of developing fibrosis of multiple internal organs, including the lung. There are no approved drugs for this disease. SSc affects approximately 124,000 patients2 in the US and Europe3, with a predominance of female patients (>80%). The primary endpoint of NOVESA is the modified Rodnan Skin Score (mRSS) at 24 weeks. mRSS me
Aducanumab is good; next generation Alzheimer’s disease therapies will be better5.12.2019 18:50:00 CET | Press release
New data for aducanumab strengthens potential for Alzheimer’s therapy in near term, fuels next-generation therapies with more selective binding for toxic species of amyloid beta TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen for its trailblazing efforts to advance aducanumab. Data released today at CTAD (Clinical Trials on Alzheimer’s Disease conference) strengthen aducanumab’s potential to become the first disease-modifying therapy for Alzheimer’s disease. The data clearly underscore the need for next-generation drug candidates that offer more precise binding to the misfolded beta amyloid oligomer (AßO), the toxic species of the amyloid beta protein and root cause of Alzheimer’s disease. “Today’s presentation reflects yet ano
Olainfarm invites to Third Quarter 2019 Investor Conference Webinar5.12.2019 18:17:00 CET | Press release
JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on December 11, 2019 at 16:00 (EET). To join the webinar please follow the instructions below. Webinar will be hosted by the Chairman of Management Board Jeroen Weites and Investor Relations Advisor Janis Dubrovskis. The presentation will be held in English. During the webinar JSC Olainfarm representatives will inform about the recent performance of the company and financial results of third quarter and 9 months of 2019. After the presentation investors are welcome to ask questions. Due to the limited webinar time please send in your questions in advance to e-mail: email@example.com. What is a webinar? Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask questions and get answe
Auction details Inflation-linked bonds5.12.2019 16:20:00 CET | Press release
Auction date December 12, 2019 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2027-12-01 3113 SE0009548704 0.125% 500 Settlement date December 16, 2019 Bids have to be entered by 11.00 on December 12, 2019 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 firstname.lastname@example.org